Fundies, anybody? Here's the latest in scrip sales, that you might judge the market your fave biotech is trying for . . .
>>IMS HEALTH Reports 14.9 Percent Growth in U.S. Prescription Sales to $145 Billion in 2000
Cholesterol reducers lead therapeutic classes with U.S. sales of $9 billion; Prilosec leads in prescription product sales
WESTPORT, Conn--(BW HealthWire)--May 31, 2001-- IMS HEALTH (NYSE: RX - news) today reported that U.S. prescription drug sales grew 14.9 percent to $145 billion in 2000, compared with $126 billion in sales the previous year.
Prescription product sales data are derived from IMS HEALTH's Retail and Provider Perspective(TM) service and reflect wholesale prices. IMS HEALTH is the world's leading provider of information solutions to the pharmaceutical and healthcare industries.
``New and more effective drug therapies, an aging population and growing consumer demand have all fueled an increase in the volume of drugs dispensed -- the primary driver of U.S. sales growth,'' said Paul Wilson, IMS HEALTH vice president and chief statistician. ``Nearly two-thirds of sales growth can be attributed to higher prescription volume, with just slightly more than one-quarter coming from price increases and the balance from new product introductions.''
Of the 14.9 percent increase in 2000 prescription product sales, 8.9 percent resulted from a higher number of prescriptions dispensed, 3.9 percent from price increases and 2.1 percent from the introduction of new medicines. Quarterly price activity in the U.S. pharmaceutical market is tracked through IMS HEALTH's Pharmaceutical Pricing UPDATE(TM).
Leading U.S. Therapy Classes
The top-10 therapy classes accounted for 37 percent of total U.S. prescription sales in 2000. Six of these leading classes grew by more than 20 percent.
Cholesterol reducers were the leading class last year, with sales of $9 billion. COX-2 Inhibitor sales grew the fastest of the top-10 therapy classes, with 105.4 percent growth in 2000 due to demand for Pharmacia's Celebrex and Merck's Vioxx.
Table 1
Top 10 Therapeutic Classes by U.S. Prescription Sales in 2000
2000 Percent Growth
Sales Year-Over-Year
(US$B)
1 Cholesterol Reducers $9.0 24.9%
2 SSRI/SNRI 8.3 19.2
3 Proton Pump Inhibitors 8.3 25.8
4 Cytostatics 5.3 7.5
5 Calcium Blockers 4.5 (1.8)
6 Antipsychotics 4.0 27.6
7 Erythropoietins 3.9 26.8
8 COX-2 Inhibitors 3.7 105.4
9 Seizure Disorders 3.5 28.3
10 Ace Inhibitors 3.5 4.6
Total $54.0 21.7%
Source: IMS HEALTH Retail and Provider Perspective, reflecting
wholesale prices. Sales include prescription products only. Insulin
products are not included.
Leading U.S. Prescription Products
Astra-Zeneca's Prilosec remained the leading U.S. prescription
drug in 2000, with 10.4 percent year-over-year growth and sales of
$4.6 billion. Pfizer's Lipitor was ranked second with $4.1 billion in
sales and 38.3 percent growth.
TAP's Prevacid rose from fourth place a year ago to the No.
3-ranked position in 2000, as Eli Lilly's Prozac dropped from third to
fifth place. Sales of Merck's Zocor, in fourth position, grew 21.7
percent in 2000.
Table 2
Top 10 U.S. Prescription Products by Sales in 2000
2000 Sales Percent Growth Market Share
(US$B) Year-Over-Year In 2000
1 Prilosec $4.6 10.4% 3.2%
2 Lipitor 4.1 38.3 2.9
3 Prevacid 3.1 33.3 2.2
4 Zocor 2.8 21.7 1.9
5 Prozac 2.7 3.8 1.8
6 Celebrex 2.2 52.1 1.5
7 Epogen 2.1 12.3 1.4
8 Zoloft 2.0 14.1 1.4
9 Zyprexa 1.9 27.7 1.3
10 Procrit 1.9 47.8 1.3
Total $27.3 23.5% 19.0%
Source: IMS HEALTH Retail and Provider Perspective, reflecting
wholesale prices. Sales include prescription products only. Insulin
products are not included.
Largest Pharmaceutical Companies by U.S. Sales
The five largest pharmaceutical companies, as measured by U.S.
prescription product sales, accounted for 39 percent of total U.S.
prescription sales in 2000, up from 30 percent in 1999.
Merger activity shifted the ranking of the largest pharmaceutical
companies. Pfizer, now combined with Warner-Lambert, surpassed Merck
to become the leading U.S. pharmaceutical company in 2000 as measured
by prescription sales. The merger of Glaxo and SmithKline Beecham
elevated GlaxoSmithKline to the No. 2 position.
Table 3
Top 10 Pharmaceutical Companies by U.S. Prescription Sales in 2000
2000 Percent Growth Market Share
Sales Year-Over-Year In 2000
(US$B)
1 Pfizer $15.3 11.4% 10.6%
2 GlaxoSmithKline 13.0 19.0 8.9
3 Merck and Co. 10.8 22.4 7.4
4 Bristol-Myers Squibb 9.0 13.7 6.2
5 AstraZeneca 8.5 13.5 5.9
6 Johnson & Johnson 7.9 17.7 5.4
7 Pharmacia 6.3 16.1 4.3
8 Lilly 6.1 14.4 4.2
9 American Home Products 6.0 12.6 4.2
10 Schering Plough 5.8 3.4 3.4
Total $88.8 14.9% 61.2%
Source: IMS HEALTH Retail and Provider Perspective, reflecting
wholesale prices. Sales include prescription products only. Insulin
products are not included.
U.S. Prescription Distribution Channels
Retail pharmacies remained the primary distribution channel for
U.S. prescription drugs in 2000, capturing 64.3 percent market share
and growing at a 14.4 percent annual rate. Mail order sales, the
fastest-growing distribution channel, rose 26.5 percent, capturing
11.1 percent of distribution market share.
Prescription sales in several non-retail channels outpaced overall
U.S. prescription sales growth in 2000: Clinics and long-term care
facilities each grew more than 21 percent, increasing their market
share to 7.2 percent and 3.1 percent, respectively.
Home health care prescriptions, an emerging channel reported by
IMS HEALTH for the first time in 2000, accounted for approximately 1
percent of total U.S. pharmaceutical sales.
Table 4
U.S. Prescription Market Share by Distribution Channel
2000 Percent Growth Market Share
Sales Year-Over-Year In 2000
(US$B)
1 Chain Stores $54.9 14.5% 37.8%
2 Independent 25.2 9.3 17.4
3 Mail Order 16.1 26.5 11.1
4 Food Stores 13.1 26.2 9.0
5 Non-Federal Hospitals 15.6 5.3 10.7
6 Clinics 10.4 21.3 7.2
7 Long-Term Care 4.5 21.8 3.1
8 Federal Facilities 2.4 13.5 1.7
9 Home Health Care 1.6 16.0 1.1
10 HMO 1.4 (5.8) .98
Total $145.0 14.9% 100%
Source: IMS HEALTH Retail and Provider Perspective, reflecting
wholesale prices. Sales include prescription products only. Insulin
products are not included.
IMS HEALTH is the world's leading provider of information solutions to the pharmaceutical and healthcare industries. With $1.3 billion in 2000 revenue, IMS HEALTH operates in more than 100 countries. IMS HEALTH is the largest pharmaceutical manufacturer information partner, with over 45 years' experience in the industry. Key products and services integral to customer day-to-day operations include market research for prescription and over-the-counter pharmaceutical products and sales management information to optimize sales force productivity. Additional information is available at imshealth.com.<<
snip
Cheers, Tuck |
